Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02492997
Recruitment Status : Terminated (Trial was terminated early due to slow enrollment.)
First Posted : July 9, 2015
Results First Posted : November 17, 2020
Last Update Posted : November 17, 2020
Sponsor:
Information provided by (Responsible Party):
Venus Concept

Brief Summary:
The octipolar applicator is intended for circumference reduction treatment by reduction of adipose size and enhancement of collagen synthesis as the result thermal and non-thermal collagen stimulation. This trial is intended to evaluate the effect of radio frequency (RF) and pulsed electromagnetic fields (PEMF) treatment on circumference reduction.

Condition or disease Intervention/treatment Phase
Lipodystrophy Device: Venus Versa Other: Glycerine gel Not Applicable

Detailed Description:

This is a multi-site, prospective, controlled, randomized, double blinded clinical trial. This study is designed to evaluate the safety and efficacy of a series of treatments using the Venus Versa Octipolar applicator. Up to 60 healthy subjects at 10 sites shall be recruited by the investigator from within the investigator's subject population. Subjects shall have abdomen circumference to reduce for the designated treatment area.

Each subject will undergo 6 treatments at an interval of one treatment per week for six consecutive weeks. There will be a one month follow up which will occur 4 weeks after the 6th treatment.

At the first treatment visit, the investigator will collect demographic and medical information and randomization will take place. Subjects have an equal opportunity to be selected for the treatment or the control group.

The duration of the treatment session will be approximately 60 minutes. Expected immediate response includes temporary mild to moderate erythema and/or edema. Skin safety assessments will be conducted by the investigator after each treatment session and at the follow-up visit.

Photography will be conducted at baseline, the beginning of 4th & 6th treatment and at 1 month follow up visit. Subjects will be asked to complete a questionnaire after each treatment and at the one month follow up visit.

Circumference measurements will be conducted at base line, before each treatment and at follow up visit. The treatment will be considered successful if the treated area circumference, reduces by at least 2.5 cm.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
Actual Study Start Date : May 14, 2015
Actual Primary Completion Date : October 25, 2016
Actual Study Completion Date : October 31, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Glycerin

Arm Intervention/treatment
Experimental: Treatment Group
Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
Device: Venus Versa
The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.

Other: Glycerine gel
Gel used to protect the skin from the RF energy and to assist with energy distribution

Sham Comparator: Control Group
Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
Device: Venus Versa
The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.

Other: Glycerine gel
Gel used to protect the skin from the RF energy and to assist with energy distribution




Primary Outcome Measures :
  1. Abdominal Circumference [ Time Frame: 1 month post treatment series ]
    Abdominal circumference measurement of the treated area at 1 month after the last treatment performed by controlled tape measurement


Secondary Outcome Measures :
  1. Subject Satisfaction With Treatment [ Time Frame: 1 month post treatment series ]
    Subject 5-point Likert Satisfaction Assessment Scale where 4 = Very satisfied; 3 = Satisfied; 2 = Having no opinion; 1 = Unsatisfied and 0 = Very unsatisfied.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
  • Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.
  • For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, Intra Uterine Device (IUD), contraceptive implant, barrier methods with spermicide, or abstinence).

Exclusion Criteria:

  • Pregnant or planning to become pregnant, having given birth less than 9 months ago, and/or breastfeeding.
  • Having any active electrical implant anywhere in the body,
  • Having a permanent implant in the treated areas
  • Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
  • Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 2 years of treatment
  • Having or undergoing any form of cancer
  • Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
  • Having a anticoagulative or thromboembolic condition or taking anticoagulation medications
  • History of immunosuppression/immune deficiency disorders
  • Suffering from hormonal imbalance which may affect weight or cellulite
  • History of significant lymphatic drainage problems.
  • History of keloid scarring or of abnormal wound healing.
  • History of being especially prone to bruising.
  • History of epidermal or dermal disorders
  • Use of isotretinoin within 6 months
  • Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.
  • Participation in a study of another device or drug within 1 month prior to enrollment or during this study.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02492997


Locations
Layout table for location information
United States, New Jersey
J Dermatology and Allergy
Fort Lee, New Jersey, United States, 07024
Sponsors and Collaborators
Venus Concept
Investigators
Layout table for investigator information
Study Director: Tracey L Mancuso Venus Concept
Layout table for additonal information
Responsible Party: Venus Concept
ClinicalTrials.gov Identifier: NCT02492997    
Other Study ID Numbers: CS0615
First Posted: July 9, 2015    Key Record Dates
Results First Posted: November 17, 2020
Last Update Posted: November 17, 2020
Last Verified: November 2020
Keywords provided by Venus Concept:
body fat
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipodystrophy
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Glycerol
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs